AAPL   381.57 (-0.30%)
MSFT   213.18 (-0.53%)
GOOGL   1,522.20 (+0.23%)
AMZN   3,184.58 (+0.06%)
CGC   16.97 (+5.93%)
BABA   259.28 (-0.88%)
MU   50.02 (+0.08%)
GE   6.67 (+1.37%)
TSLA   1,492.82 (+7.07%)
F   6.04 (+3.25%)
GILD   76.31 (+2.14%)
DIS   118.94 (+1.81%)
BAC   23.90 (+4.96%)
NFLX   550.15 (+8.35%)
BA   178.44 (+2.98%)
AAPL   381.57 (-0.30%)
MSFT   213.18 (-0.53%)
GOOGL   1,522.20 (+0.23%)
AMZN   3,184.58 (+0.06%)
CGC   16.97 (+5.93%)
BABA   259.28 (-0.88%)
MU   50.02 (+0.08%)
GE   6.67 (+1.37%)
TSLA   1,492.82 (+7.07%)
F   6.04 (+3.25%)
GILD   76.31 (+2.14%)
DIS   118.94 (+1.81%)
BAC   23.90 (+4.96%)
NFLX   550.15 (+8.35%)
BA   178.44 (+2.98%)
AAPL   381.57 (-0.30%)
MSFT   213.18 (-0.53%)
GOOGL   1,522.20 (+0.23%)
AMZN   3,184.58 (+0.06%)
CGC   16.97 (+5.93%)
BABA   259.28 (-0.88%)
MU   50.02 (+0.08%)
GE   6.67 (+1.37%)
TSLA   1,492.82 (+7.07%)
F   6.04 (+3.25%)
GILD   76.31 (+2.14%)
DIS   118.94 (+1.81%)
BAC   23.90 (+4.96%)
NFLX   550.15 (+8.35%)
BA   178.44 (+2.98%)
AAPL   381.57 (-0.30%)
MSFT   213.18 (-0.53%)
GOOGL   1,522.20 (+0.23%)
AMZN   3,184.58 (+0.06%)
CGC   16.97 (+5.93%)
BABA   259.28 (-0.88%)
MU   50.02 (+0.08%)
GE   6.67 (+1.37%)
TSLA   1,492.82 (+7.07%)
F   6.04 (+3.25%)
GILD   76.31 (+2.14%)
DIS   118.94 (+1.81%)
BAC   23.90 (+4.96%)
NFLX   550.15 (+8.35%)
BA   178.44 (+2.98%)
Log in

NASDAQ:NVAXNovavax Stock Price, Forecast & News

$94.32
-1.98 (-2.06 %)
(As of 07/10/2020 02:36 PM ET)
Add
Compare
Today's Range
$93.51
Now: $94.32
$98.61
50-Day Range
$44.25
MA: $60.15
$104.56
52-Week Range
$3.54
Now: $94.32
$111.77
Volume2.40 million shs
Average Volume8.20 million shs
Market Capitalization$5.47 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.5
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen. The company also develops RSV F vaccine for older adults in Phase II clinical trial, and healthy children between two and six years of age in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus in Phase I clinical trial, as well as MERS coronavirus in animals; and combination respiratory vaccine to protect against influenza and RSV. The company has a clinical development agreement with Bill & Melinda Gates Foundation. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Read More
Novavax logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NVAX
CUSIP67000210
Phone240-268-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.66 million
Book Value($5.75) per share

Profitability

Net Income$-132,690,000.00
Net Margins-638.76%

Miscellaneous

Employees373
Market Cap$5.47 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.

Novavax (NASDAQ:NVAX) Frequently Asked Questions

How has Novavax's stock been impacted by COVID-19 (Coronavirus)?

Novavax's stock was trading at $10.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NVAX shares have increased by 796.4% and is now trading at $94.21. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Novavax?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novavax.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Novavax.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.58) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by $0.09. The biopharmaceutical company had revenue of $3.38 million for the quarter, compared to the consensus estimate of $3.50 million. During the same quarter in the prior year, the company earned ($2.20) earnings per share. View Novavax's earnings history.

When did Novavax's stock split? How did Novavax's stock split work?

Novavax shares reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for NVAX?

7 brokerages have issued 1-year target prices for Novavax's stock. Their forecasts range from $15.00 to $148.00. On average, they anticipate Novavax's stock price to reach $79.93 in the next year. This suggests that the stock has a possible downside of 15.2%. View analysts' price targets for Novavax.

Has Novavax been receiving favorable news coverage?

Headlines about NVAX stock have trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novavax earned a news impact score of 1.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Novavax.

Who are some of Novavax's key competitors?

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Egalet (EGLT), EXACT Sciences (EXAS), Palo Alto Networks (PANW), Akebia Therapeutics (AKBA), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Cara Therapeutics (CARA), NVIDIA (NVDA) and AT&T (T).

Who are Novavax's key executives?

Novavax's management team includes the following people:
  • Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)
  • Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)
  • Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)
  • Dr. Gregory M. Glenn, Pres of R&D (Age 65)
  • Ms. Erika S. Trahan, Sr. Mang. of Investor & PR

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $94.21.

How big of a company is Novavax?

Novavax has a market capitalization of $5.46 billion and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Novavax employs 373 workers across the globe.

What is Novavax's official website?

The official website for Novavax is www.novavax.com.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.